Baird Financial Group Inc. Sells 976 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Baird Financial Group Inc. reduced its stake in Thermo Fisher Scientific by 0.5%, now owning approximately 212,811 shares valued at around $105.9 million.
• Wall Street analysts are optimistic about Thermo Fisher Scientific, with several firms maintaining or raising their target prices and ratings, reflecting a consensus price target of $593.00.
• The company recently announced a quarterly dividend of $0.43 per share, with a scheduled payment date of October 15th and an annualized dividend yield of 0.3%.

Baird Financial Group Inc. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 212,811 shares of the medical research company's stock after selling 976 shares during the quarter. Baird Financial Group Inc. owned 0.06% of Thermo Fisher Scientific worth $105,895,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Revolve Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Port Capital LLC lifted its position in Thermo Fisher Scientific by 1.6% in the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after acquiring an additional 22 shares in the last quarter. Clark Capital Management Group Inc. lifted its position in Thermo Fisher Scientific by 0.5% in the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after acquiring an additional 23 shares in the last quarter. Monograph Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 0.3% in the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after acquiring an additional 23 shares in the last quarter. Finally, Intergy Private Wealth LLC lifted its position in Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after acquiring an additional 23 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. UBS Group lifted their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Finally, Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $3.31 during trading on Monday, hitting $493.05. 1,228,194 shares of the stock were exchanged, compared to its average volume of 1,834,312. The stock has a market capitalization of $186.18 billion, a price-to-earnings ratio of 28.52, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75. The company has a fifty day moving average price of $454.36 and a 200-day moving average price of $453.50. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock worth $13,603,438 over the last 90 days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.